$7.9M
+$7.9M this year1 filing since 2026 · latest SAFE filed
Cadrenal Therapeutics is a late-stage biopharmaceutical company in Ponte Vedra, Florida developing treatments for life-threatening immune and thrombotic conditions. It is publicly traded on Nasdaq under the ticker CVKD and was founded in 2022 by Chairman and CEO Quang X. Pham. Its lead program, CAD-1005, is a first-in-class 12-LOX inhibitor for heparin-induced thrombocytopenia that is Phase 3-ready and carries FDA Orphan Drug and Fast Track designations. The pipeline also includes tecarfarin, an oral vitamin K antagonist anticoagulant, and frunexian, an intravenous Factor XIa inhibitor for acute hospital settings.
What sets it apart
CAD-1005 targets the underlying immune mechanism of heparin-induced thrombocytopenia by selectively inhibiting 12-LOX, whereas existing HIT therapies only manage the resulting clotting complications; tecarfarin likewise uses a different metabolic pathway than warfarin, aimed at patients such as those with end-stage kidney disease or left ventricular assist devices where warfarin control is unreliable.
A first-in-class 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia (HIT), an immune-mediated thrombotic disorder. It is Phase 3-ready and holds FDA Orphan Drug and Fast Track designations.
